Savara Inc (OQ:SVRA)

Sep 11, 2020 08:05 am ET
Savara Announces Senior Management Changes
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CEO) and from the Board of Directors, effective immediately, to pursue other opportunities. The Company’s Board of Directors has appointed Matthew Pauls as Chairman and I
Sep 09, 2020 04:05 pm ET
Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT.
Sep 08, 2020 08:05 am ET
Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The manuscript, titled “Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis,” appears in the September 7, 2020 online version of the publication and can be found at www.nejm.org.
Sep 03, 2020 04:05 pm ET
Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF). Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), was also evaluated for the treatment of NTM in non-CF patients in the Phase 2a OPTIMA study that completed in March 2020.
Aug 06, 2020 04:02 pm ET
Savara Reports Second Quarter 2020 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.
Aug 05, 2020 08:05 am ET
Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth Conference on Wednesday, August 12, 2020 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time.
Jul 30, 2020 08:05 am ET
Savara to Report Second Quarter 2020 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6, 2020. Savara management will host a conference call/webcast at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
May 27, 2020 04:05 pm ET
 Savara to Present at the Jefferies Virtual Healthcare Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 10:30 a.m. ET / 7:30 a.m. PT.
May 08, 2020 08:05 am ET
Savara Announces Change of Date for 2020 Annual Meeting of Stockholders
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced a change in the date, time, and format of its 2020 Annual Meeting of Stockholders due to public health and safety concerns related to the COVID-19 pandemic and in the interest of the health and well-being of stockholders and other meeting participants. The Annual Meeting will
May 07, 2020 04:05 pm ET
Savara Reports First Quarter 2020 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the first quarter ending March 31, 2020 and provided a business update.
Apr 30, 2020 04:05 pm ET
Savara to Report First Quarter 2020 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report first quarter 2020 financial results and provide a business update on Thursday, May 7, 2020. Savara management will host a conference call/webcast at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
Apr 02, 2020 04:05 pm ET
Savara Obtains Global Rights to Develop and Commercialize Apulmiq
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the Company has entered into an exclusive license and collaboration agreement with Grifols for Apulmiq (inhaled liposomal ciprofloxacin). Also known as Linhaliq in Europe, Apulmiq is a late-stage investigational inhaled antibiotic in Phase 3 development for the treatment of non-cystic fibrosis bronchiectasis (NCFB).
Mar 30, 2020 04:05 pm ET
Savara Provides Business Update in Response to COVID-19 Pandemic
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on the impact COVID-19 has had on two of the Company’s clinical studies in cystic fibrosis (CF). Due to the COVID-19 pandemic, and out of an abundance of caution for people living with CF and clinical study staff, enrollment has been terminated in the Phase 3 AVAIL and the Phase 2a ENCORE studies. With patient safety at the forefront of the decision, and in accordance with guidelines established by the U.S. Food and Drug Administration (FDA), efforts will be made to allow enrolled patients to continue with stu
Mar 12, 2020 04:05 pm ET
Savara Reports Fourth Quarter / Year-End 2019 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the fourth quarter and full year ending December 31, 2019 and provided a business update.
Mar 05, 2020 08:05 am ET
Savara to Report Fourth Quarter/Year-End 2019 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report fourth quarter/year-end 2019 financial results and provide a business update on Thursday, March 12, 2020. Savara management will host a conference call/webcast at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
Dec 30, 2019 08:05 am ET
Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP.
Dec 20, 2019 11:51 am ET
Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it has entered into a definitive agreement for a private placement with institutional investors to purchase an aggregate of 9,569,430 shares of common stock and, in lieu of shares of common stock, pre-funded warrants to purchase an aggregate of 5,780,537 shares of common
Dec 03, 2019 04:05 pm ET
Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the appointment of Dr. An van Es-Johansson, M.D. to its Board of Directors, effective immediately. Dr. van Es-Johansson has extensive experience in the development of FDA- and EMA-approved orphan products and has held global leadership roles across multiple disciplines of the
Nov 27, 2019 04:05 pm ET
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that on November 26, 2019, the independent members of the Company's Board of Directors granted Badrul Chowdhury, M.D., Ph.D., the Company's new Chief Medical Officer, an option to purchase 300,000 shares of the Company's common stock with an exercise price of $1.01 per share,
Nov 26, 2019 04:05 pm ET
Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, will be presenting at the Evercore ISI HealthCONx conference on Wednesday, December 4, 2019 at 2:20 PM ET / 11:20 AM PT at the Four Seasons Hotel in Boston. Taneli Jouhikainen, Savara’s President and Chief Operating Officer, and Badrul Chowdhury, Savara’s Chief Medical Officer, will participa
Nov 18, 2019 08:05 am ET
Savara Appoints Badrul Chowdhury, M.D., Ph.D as Chief Medical Officer
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the appointment of Badrul Chowdhury, M.D., Ph.D., to the newly created position of Chief Medical Officer (CMO), effective immediately. Dr. Chowdhury will be Savara’s senior physician overseeing the medical and regulatory strategy of the Company’s investigational programs from late-stage development through to approval. He will also provide oversight of medical affairs and patient safety across the portfolio.
Nov 13, 2019 02:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. – SVRA
Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The...
Nov 12, 2019 04:05 pm ET
Savara to Present at the Stifel 2019 Healthcare Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, will be presenting at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:00 PM ET / 12:00 PM PT at the Lotte New York Palace Hotel. Rob Neville, Savara’s Chief Executive Officer, will represent the Company at the conference.
Nov 07, 2019 05:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA
Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The...
Nov 07, 2019 04:05 pm ET
Savara Reports Third Quarter 2019 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2019 and provided a business update.
Oct 31, 2019 04:05 pm ET
Savara to Report Third Quarter 2019 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report third quarter 2019 financial results and provide a business update on Thursday, November 7, 2019. Savara management will host a conference call/webcast with an accompanying slide deck at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
Oct 02, 2019 06:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. – SVRA
Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The...
Oct 02, 2019 08:02 am ET
Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the response from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the Molgradex development program for autoimmune pulmonary alveolar proteinosis (aPAP). Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-
Sep 18, 2019 04:15 pm ET
Savara to Present Comprehensive Data From Pivotal Phase 3 IMPALA Study at 2019 ERS
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that additional data from IMPALA, an ongoing pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) will be presented at
Aug 08, 2019 04:02 pm ET
Savara Reports Second Quarter 2019 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2019 and provided a business update.
Aug 01, 2019 08:02 am ET
Savara to Report Second Quarter 2019 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2019 financial results and provide a business update on Thursday, August 8, 2019. Savara management will host a conference call at 4:30 p
Jul 31, 2019 08:02 am ET
Savara to Present at the 39th Annual Canaccord Genuity Global Growth Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Operating Officer, Taneli Jouhikainen, will present at the Canaccord Genuity Global Growth Conference on Wednesday, August 7, 2019 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time in the Montreal Room at the Intercontinental in Boston.
Jun 13, 2019 04:02 pm ET
Savara to Present at the JMP Securities Life Sciences Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, and Chief Operating Officer, Taneli Jouhikainen, will present at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time in
Jun 12, 2019 04:02 pm ET
Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced top line data from IMPALA, a pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP. 138 patients were randomized and received t
May 09, 2019 04:02 pm ET
Savara Reports First Quarter 2019 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the first quarter ending March 31, 2019 and provided a business update.
May 06, 2019 08:02 am ET
Savara Announces Molgradex Received Fast Track Designation by FDA for Treatment of Autoimmune Pulmonary Alveolar Proteinosis
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Molgradex, an inhaled formulation of recombinant human granulocyte-
May 02, 2019 08:02 am ET
Savara to Report First Quarter 2019 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report first quarter 2019 financial results and provide a business update on Thursday, May 9, 2019. Savara management will host a
Apr 02, 2019 08:00 am ET
Savara to Present at the H.C. Wainwright Global Life Sciences Conference in London
AUSTIN, TX / ACCESSWIRE / April 2, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that Rob Neville, Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences conference on Tuesday, April 9, 2019 at 1:50 PM GMT / 8:50 AM EST. The conference will be held at the JW Marriott Grosvenor House London.
Apr 01, 2019 08:00 am ET
Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection in People Living with Cystic Fibrosis
AUSTIN, TX / ACCESSWIRE / April 1, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced the initiation of ENCORE, a Phase 2a clinical study evaluating its lead product candidate, Molgradex, for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF). Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and is also currently in Phase 2a development for NTM in non-CF patients and in Phase 3 devel
Mar 13, 2019 04:02 pm ET
Savara Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update
On-Track to Report Top Line Results from Pivotal Phase 3 IMPALA Study at End of Q2 2019
Mar 06, 2019 08:00 am ET
Savara To Report Q4/Year-End 2018 Financial Results And Business Update On March 13, 2019
AUSTIN, TX / ACCESSWIRE / March 6, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its fourth quarter and year-end 2018 financial results on Wednesday, March 13, 2019. Savara management will also host a conference call for investors at 5:30 p.m. ET/2:30 p.m. PT on Wednesday, March 13, 2019 to discuss its fourth quarter and year-end 2018 financial results and provide a business update.
Mar 04, 2019 08:00 am ET
Savara to Present at the 39th Annual Cowen and Company Healthcare Conference
AUSTIN, TX / ACCESSWIRE / March 4, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, announced today that the company's Chief Executive Officer, Rob Neville, will present at the 39th Annual Cowen and Company Healthcare Conference on Monday, March 11, 2019 at 2:10 p.m. Eastern Time in Salon B of the Boston Marriott Copley Place in Boston.
Feb 06, 2019 08:00 am ET
Savara Provides Update on IMPALA and AVAIL Pivotal Clinical Studies
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on its two pivotal Phase 3 clinical studies, IMPALA and AVAIL. IMPALA IMPALA is a pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of...
Dec 19, 2018 08:00 am ET
Savara Announces Interim Results for OPTIMA Clinical Study of Molgradex for the Treatment of NTM
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced interim results from OPTIMA, a Phase 2a clinical study evaluating its lead product candidate Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage...
Nov 16, 2018 08:00 am ET
Savara to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27th
Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that Rob Neville, Savara’s Chief Executive Officer, will participate in a fireside chat at the Evercore ISI HealthCONx Conference in Boston on Tuesday, November 27, 2018 at...
Nov 07, 2018 04:02 pm ET
Savara Reports Third Quarter 2018 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2018 and provided a business update. “We are creating a differentiated orphan lung disease company through a...
Nov 01, 2018 08:00 am ET
Savara to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 7, 2018
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its third quarter 2018 financial results on Wednesday, November 7, 2018. Savara management will also host a conference call for investors beginning at 5:30...
Oct 31, 2018 08:00 am ET
Savara Completes Enrollment in Molgradex OPTIMA Clinical Study for the Treatment of NTM
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced completion of the target enrollment of 30 patients in OPTIMA, a Phase 2a clinical study evaluating its lead product candidate Molgradex, an inhaled formulation of...
Oct 15, 2018 08:00 am ET
Savara Completes Enrollment in Pivotal Molgradex Impala Clinical Study for the Treatment of aPAP
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced completion of the target enrollment of 135 patients in IMPALA, its global pivotal Phase 3 clinical study evaluating its lead product candidate Molgradex, an inhaled...
Sep 27, 2018 08:00 am ET
Savara Provides Enrollment Update on Molgradex Impala and OPTIMA Clinical Studies and Reaffirms Guidance for Topline Data
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided patient enrollment updates for its Molgradex pivotal Phase 3 clinical study, IMPALA, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), as well as its...
Aug 27, 2018 08:00 am ET
Savara Becomes Inaugural Foundation Sponsor of the PAP Foundation
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, is pleased to announce a global partnership with the PAP Foundation, Inc., a non-profit patient advocacy organization dedicated to improving the lives of those affected by PAP, where...
Aug 09, 2018 04:03 pm ET
Savara Reports Second Quarter 2018 Financial Results and Provides Positive Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today reported financial results for the second quarter ended June 30, 2018 and provided a business update. “We have had an incredibly eventful and productive quarter,” said Rob...
Aug 02, 2018 08:00 am ET
Savara to Host Second Quarter 2018 Financial Results and Business Update Conference Call on Thursday, August 9, 2018
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its second quarter 2018 financial results on Thursday, August 9, 2018. Savara management will also host a conference call for investors beginning at 5:30...
Jul 26, 2018 09:15 am ET
Savara Announces Pricing of Public Offering of Common Stock
Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock at a price to the public of $11.50 per share. The expected gross proceeds of the...
Jul 25, 2018 04:16 pm ET
Savara Announces Proposed Public Offering of Common Stock
Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. The offering is subject to market and other...
Jul 25, 2018 04:01 pm ET
Savara Provides Positive Update on Development and Commercial Preparations of Molgradex, Including Expansion into NTM In CF
Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today provided an update on the clinical development and commercial preparatory efforts for its lead product candidate Molgradex, an inhaled formulation of recombinant human...
Jul 23, 2018 08:00 am ET
Savara to Ring Nasdaq Stock Market Opening Bell on July 23rd
Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, announced today that Rob Neville, CEO of Savara, alongside key members of senior management, company directors, and employees, will ring the Nasdaq Stock Market Opening Bell today, July...
Jun 25, 2018 08:00 am ET
Savara Joins Russell 3000® Index
Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that the company has been added to the broad-market Russell 3000 Index. “In the little more than one year since transitioning to the public markets, Savara’s inclusion in...
Jun 13, 2018 08:00 am ET
Savara to Present at JMP Securities 2018 Life Sciences Conference on June 20th
Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that the company's Chief Executive Officer, Rob Neville, will present at the JMP Securities 2018 Life Sciences Conference on Wednesday June 20, 2018 at 3:30 p.m. Eastern...
May 29, 2018 08:00 am ET
Savara Provides Update on Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of Nontuberculous Mycobacteria Infection
Savara, Inc. (NASDAQ:SVRA), an orphan lung disease company, today provided an update on two case reports exploring the use of aerosolized granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of Mycobacterium abscessus (M....
May 23, 2018 08:25 am ET
New Research: Key Drivers of Growth for PCM, WGL, Savara, ConforMIS, Sandy Spring, and West Pharmaceutical Services — Factors of Influence, Major Initiatives and Sustained Production
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PCM, Inc. (NASDAQ:PCMI), WGL Holdings Inc (NYSE:WGL), Savara Inc....
May 15, 2018 12:26 pm ET
UPDATE -- Savara to Present at Bank of America Merrill Lynch 2018 Healthcare Conference on May 15th
Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that the Company's Chief Executive Officer, Rob Neville, will present at the Bank of America Merrill Lynch 2018 Healthcare Conference on Tuesday May 15th, 2018 at 1:55 p.m....
May 11, 2018 08:00 am ET
Savara to Present at Bank of America Merrill Lynch 2018 Healthcare Conference on May 17th
Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that the Company's Chief Executive Officer, Rob Neville, will present at the Bank of America Merrill Lynch 2018 Healthcare Conference on Tuesday May 15th, 2018 at 1:55 p.m....
May 09, 2018 04:02 pm ET
Savara Reports First Quarter 2018 Financial Results and Provides Business Update
Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today reported financial results for the first quarter ended March 31, 2018 and provided a business update. “It has been an incredibly productive quarter, including the launch of two new...
May 01, 2018 08:00 am ET
Savara to Host First Quarter 2018 Financial Results and Business Update Conference Call on Wednesday, May 9, 2018
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its first quarter 2018 financial results on Wednesday, May 9, 2018. Savara management will also host a conference call for investors beginning at 5:30 p.m....
Mar 30, 2018 07:45 am ET
Report: Exploring Fundamental Drivers Behind Mast Therapeutics, Pebblebrook Hotel Trust, Smart, Waddell & Reed Financial, Quality Care Properties, and Meridian Waste Solutions — New Horizons, Emerging
NEW YORK, March 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mast Therapeutics, Inc. (NASDAQ:SVRA), Pebblebrook Hotel...
Mar 15, 2018 08:00 am ET
Savara to Present at 28th Annual Oppenheimer & Co. Healthcare Conference on March 20th
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, announced today that the Company's Chief Executive Officer, Rob Neville, will present at the 28th Annual Oppenheimer & Co. Healthcare Conference on Tuesday, March 20th, 2018 at 1:35...
Mar 14, 2018 04:05 pm ET
Savara Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Anticipating completion of enrollment in Molgradex Phase 3 IMPALA study in Q3 2018Anticipating completion of enrollment in AeroVanc Phase 3 AVAIL study in Q1 2019Anticipating completion of enrollment in Molgradex Phase 2a OPTIMA study in Q3...
Mar 13, 2018 08:00 am ET
Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, announced today the initiation of a Phase 2a clinical study, OPTIMA, evaluating its lead product candidate Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage...
Mar 11, 2018 10:45 am ET
Aironite Fails to Meet Primary Endpoint in the Indie Phase 2 Clinical Study Conducted by the Heart Failure Clinical Research Network
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced results from the INDIE study of Aironite (sodium nitrite inhalation solution) evaluating the use of inhaled inorganic nitrite for symptom relief in patients with heart...
Mar 07, 2018 08:00 am ET
Savara to Host Fourth Quarter & Fiscal Year End 2017 Financial Results and Business Update Conference Call on Wednesday March 14, 2018
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that it will release its fourth quarter and fiscal year end 2017 financial results on Wednesday, March 14, 2018. Savara management will also host a conference call for...
Feb 16, 2018 08:00 am ET
Top Line Results From Aironite Phase 2 Clinical Trial for the Treatment of HFpEF to Be Presented at American College of Cardiology 67th Annual Scientific Sessions & Expo on March 11th
Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today reported that top line results from the multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial of Aironite, a sodium nitrite solution for inhalation via...
Feb 12, 2018 08:00 am ET
Savara Announces IND Approval for Expansion of Molgradex Phase 3 Study Into U.S.
Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application for Molgradex, an inhaled formulation of recombinant human...
Feb 06, 2018 08:00 am ET
Savara Reports Publication of Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of Nontuberculous Mycobacteria
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, reports the publication of two case reports exploring the use of aerosolized granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of Mycobacterium abscessus (M....
Feb 05, 2018 08:00 am ET
Savara to Present at the 20th Annual BIO CEO & Investor Conference on February 12th
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the 20th Annual BIO CEO & Investor Conference on Monday, February 12th, 2018 at 3:00 p.m....
Jan 30, 2018 08:15 am ET
Research Report Identifies Casella Waste, Savara Inc., Maximus, PCM, FARO Technologies, and Granite Point Mortgage Trust with Renewed Outlook Fundamental Analysis, Calculating Forward Movement
NEW YORK, Jan. 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Casella Waste Systems, Inc. (NASDAQ:CWST), Savara,...
Jan 04, 2018 08:00 am ET
Savara Announces Appointment of Peter Ginsberg as Vice President of Business Development
Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that Peter Ginsberg has joined the company as Vice President of Business Development. An accomplished orphan lung disease business development and investment executive, Mr....
Dec 21, 2017 08:00 pm ET
Savara Submits Investigational New Drug Application to FDA for Expansion of Molgradex Impala Study Into U.S.
Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for its lead product Molgradex, an inhaled formulation of...
Dec 18, 2017 08:00 am ET
Savara Added to Nasdaq Biotechnology Index
Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI), effective prior to the U.S. market open today, December 18, 2017. "2017 has been...
Nov 29, 2017 08:00 am ET
Savara Receives $5 Million Award From Cystic Fibrosis Foundation Therapeutics, Inc. for the Development of AeroVanc
Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that it has received a development award of up to $5 million from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development...
Nov 13, 2017 08:00 am ET
Savara to Present at the Jefferies 2017 London Healthcare Conference on November 16th
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the Jefferies 2017 London Healthcare Conference on Thursday, November 16th, 2017 at 12:40 p.m....
Nov 08, 2017 04:01 pm ET
Savara Reports Third Quarter 2017 Financial Results and Provides Business Update
Savara Inc. (NASDAQ: SVRA)Anticipating complete enrollment in the Molgradex Phase 3 IMPALA study in Q1 2018Initiating Phase 2a study of Molgradex for the treatment of NTM in early 2018Expecting top-line results from the Aironite Phase 2 INDIE study...
Nov 01, 2017 08:00 am ET
Savara to Host Third Quarter 2017 Financial Results and Business Update Conference Call on Wednesday November 8, 2017
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that it will release its third quarter 2017 financial results on Wednesday, November 8, 2017. Savara management will also host a conference call for investors beginning at...
Oct 25, 2017 09:34 am ET
Savara Announces Pricing of Public Offering of Common Stock
Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a price to the public of $7.85 per share. As a component of the offering, in lieu...
Oct 24, 2017 04:05 pm ET
Savara Announces Proposed Public Offering of Common Stock
Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. In addition, Savara is offering to certain...
Oct 24, 2017 04:01 pm ET
Savara Announces Expansion of Molgradex Development to Include Treatment of Nontuberculous Mycobacterial (NTM) Lung Infection
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced its indication expansion strategy of its lead product candidate Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor...
Oct 19, 2017 08:00 am ET
Savara Announces Uplisting to the Nasdaq Global Select Market(R)
Savara, Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced that...
Oct 18, 2017 08:00 am ET
Savara Reports Completion of Enrollment in Phase 2 Clinical Trial of Aironite for the Treatment of HFpEF
Savara, Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today reported that...
Sep 26, 2017 08:00 am ET
Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc
Savara, Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the...
Sep 21, 2017 08:00 am ET
Savara to Present at the Cantor Fitzgerald 2017 Global Healthcare Conference on September 27th
Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced that the...
Sep 05, 2017 08:00 am ET
Savara to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 11th
Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced that the...
Aug 09, 2017 08:00 am ET
Savara Reports Second Quarter 2017 Financial Results and Provides Business Update
On track to initiate Phase 3 study of AeroVanc in Q3 2017On track to complete enrollment of Aironite Phase 2 INDIE study in Q4 2017On track to complete enrollment in Molgradex Phase 3 IMPALA study in Q1 2018Savara Inc. (NASDAQ: SVRA), a...
Jul 11, 2017 09:00 am ET
Positive Interim Results Of Aironite Phase 2 Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension
AUSTIN, Texas, July 11, 2017 /PRNewswire/ -- (Savara, Inc. NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today reported positive interim results from an ongoing 50-patient open-label Phase 2 study of Aironite in patients with pulmonary hypertension (PH) from multiple different etiologies. The results were presented in an invited lecture at the 4th Annual Drug Discovery and Development Symposium for Pulmonary Hypertension on July 10...
Jun 20, 2017 09:00 am ET
Savara Set To Join Russell Microcap® Index
AUSTIN, Texas, June 20, 2017 /PRNewswire/ -- Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced that the Company will join the Russell Microcap® Index at the conclusion of the Russell indexes annual reconstitution, effective at U.S. market open on June 26, 2017. Membership in the Russell Microcap® Index, which remains in place for one year, provides automatic inclusion in the appropriate growth and value sty...
Jun 07, 2017 05:35 pm ET
Savara Announces Closing Of Public Offering Of Common Stock
AUSTIN, Texas, June 7, 2017 /PRNewswire/ -- Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the closing of an underwritten public offering of 9,034,210 shares of its common stock at a price to the public of $4.75 per share, which included 613,157 shares upon the partial exercise of the underwriters' option to purchase additional shares of Savara common stock at the public offering price, less the underwri...
Jun 05, 2017 09:00 am ET
Savara To Present At The Jefferies 2017 Global Healthcare Conference On June 9th
AUSTIN, Texas, June 5, 2017 /PRNewswire/ -- Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the Jefferies 2017 Global Healthcare Conference on Friday, June 9, 2017 at 1:00 p.m. Eastern time in Ballroom 1 at the Grand Hyatt hotel in New York. ...
Jun 02, 2017 10:16 am ET
Savara Announces Pricing Of Public Offering Of Common Stock
AUSTIN, Texas, June 2, 2017 /PRNewswire/ -- Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the pricing of an underwritten public offering of 8,421,053 shares of its common stock at a price to the public of $4.75 per share, with expected gross proceeds of approximately $40.0 million. In addition, Savara has granted the underwriters a 30-day option to purchase up to 1,263,157 additional shares of its c...
Jun 01, 2017 05:01 pm ET
Savara Announces Proposed Public Offering Of Common Stock
AUSTIN, Texas, June 1, 2017 /PRNewswire/ -- Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offe...
May 10, 2017 09:00 am ET
Savara Announces Expedited U.S. Molgradex Development Strategy
AUSTIN, Texas, May 10, 2017 /PRNewswire/ -- Savara Inc. (NASDAQ: SVRA) today announced that it has received guidance from the U.S. Food and Drug Administration on the clinical program requirements for a New Drug Application submission in the U.S. for Molgradex, an inhaled formulation of recombinant human GM-CSF, for the treatment of autoimmune pulmonary alveolar proteinosis, or PAP. Based on the FDA's guidance, Savara will modify the endpoint hierarchy and statistical analyses of its ongoing IMPALA study, currently enrolling patients in Europe and Japan, to qualify the study as a pivotal Pha...
May 08, 2017 09:00 am ET
Savara Announces Issuance Of U.S. Composition Of Matter Patent Covering AeroVanc
AUSTIN, Texas, May 8, 2017 /PRNewswire/ -- Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the recent issuance of United States Patent No. 9,572,774 for "Dry Powder Vancomycin Compositions and Associated Methods" by the United States Patent and Trademark Office. The patent will provide key intellectual property protection in the U.S. for the AeroVanc program and will expire no earlier than 2032.  This aff...
May 01, 2017 09:00 am ET
Savara Secures $15 Million Loan And Security Agreement With Silicon Valley Bank
AUSTIN, Texas, May 1, 2017 /PRNewswire/ -- Savara, Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced that it has entered into a loan agreement with Silicon Valley Bank  (NASDAQGS: SIVB), the bank of the world's most innovative companies and their investors. The agreement provides for a $15 million debt facility, $7.5 million of which is immediately available to Savara. The primary use of the capital is for the rep...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.